Literature DB >> 3440569

Polymorphonuclear cell derangements in type I diabetes.

D Tater1, B Tepaut, J P Bercovici, P Youinou.   

Abstract

Polymorphonuclear cell function had been studied in 58 Type I diabetic subjects. Chemotaxis, phagocytosis, adherence, bactericidal activity, NBT reduction capacity were evaluated. We enumerated gamma Fc receptor bearing polymorphonuclear cells and the percentage of immune complexes containing polymorphonuclear cells. These data were studied in accordance with glycemic levels and the presence of infections. All polymorphonuclear functions were decreased compared to non-diabetic subjects with the exception of phagocytosis. The efficiency of the diabetic sera on normal subjects polymorphonuclear cells was decreased (bactericidal activity, chemotactic index and phagocytosis). These abnormalities were independent of the presence of infection. No correlation was found with glycemic level. The percentage of cells bearing an Fc gamma receptor was less in diabetics than in normal (70.1 +/- 17.4 vs 80.2 +/- 7.8%). The percentage of immune complexes containing polymorphonuclear cells was increased (n = 16, 9.06 +/- 4.7 vs 4.75 +/- 2.1% in normals). There again, these data are without correlation with the presence of infections or glycemic level.

Entities:  

Mesh:

Year:  1987        PMID: 3440569     DOI: 10.1055/s-2007-1011899

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Changes in phagocytic function with glycaemic control in diabetic patients.

Authors:  S M MacRury; C G Gemmell; K R Paterson; A C MacCuish
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

Review 2.  Diabetes and immunity to tuberculosis.

Authors:  Nuria Martinez; Hardy Kornfeld
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

3.  Beneficial role of amino acids in mitigating cytoskeletal actin glycation and improving F-actin content: in vitro.

Authors:  K N Sulochana; C Indra; M Rajesh; V Srinivasan; S Ramakrishnan
Journal:  Glycoconj J       Date:  2001-04       Impact factor: 2.916

4.  Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Authors:  Omamah Alfarisi; Vidya Mave; Sanjay Gaikwad; Tushar Sahasrabudhe; Geetha Ramachandran; Hemanth Kumar; Nikhil Gupte; Vandana Kulkarni; Sona Deshmukh; Sachin Atre; Swapnil Raskar; Rahul Lokhande; Madhusudan Barthwal; Arjun Kakrani; Sandy Chon; Amita Gupta; Jonathan E Golub; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Comparison of lymphomononuclear cell energy metabolism between healthy, impaired glucose intolerance and type 2 diabetes mellitus patients.

Authors:  L Ozsari; N Karadurmus; M Sahin; G Uckaya; A U Ural; M Kutlu
Journal:  Endocrine       Date:  2009-11-17       Impact factor: 3.633

6.  The role of aldose reductase inhibition in diabetic neutrophil phagocytosis and killing.

Authors:  S E Tebbs; A M Gonzalez; R M Wilson
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

7.  Beta-hydroxybutyrate abrogates formation of bovine neutrophil extracellular traps and bactericidal activity against mammary pathogenic Escherichia coli.

Authors:  Navit Grinberg; Sharon Elazar; Ilan Rosenshine; Nahum Y Shpigel
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 8.  The impact of diabetes on the pathogenesis of sepsis.

Authors:  G C K W Koh; S J Peacock; T van der Poll; W J Wiersinga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

9.  Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections.

Authors:  Sanjay Chhibber; Tarsem Kaur
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

10.  Diabetic mouse model of orthopaedic implant-related Staphylococcus aureus infection.

Authors:  Arianna B Lovati; Lorenzo Drago; Lorenzo Monti; Elena De Vecchi; Sara Previdi; Giuseppe Banfi; Carlo L Romanò
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.